Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RA mutant melanoma...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | Journal of Skin Cancer |
Online Access: | http://dx.doi.org/10.1155/2013/735282 |
id |
doaj-ee41b24ab60e4236806eb7c23f7d1e6b |
---|---|
record_format |
Article |
spelling |
doaj-ee41b24ab60e4236806eb7c23f7d1e6b2020-11-25T01:49:46ZengHindawi LimitedJournal of Skin Cancer2090-29052090-29132013-01-01201310.1155/2013/735282735282Latest Approved Therapies for Metastatic Melanoma: What Comes Next?Farid Menaa0Department of Oncology, Stem Cells and Nanomedicine, Fluorotronics, Inc., 2453 Cades Way, Building C, San Diego, CA 92081, USANowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RA mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, the newly-approved immunotherapeutic, ipilimumab, produces durable responses in patients presenting CTLA-4 T-cell surface protein. Nevertheless, the possible synergy in combining these two therapeutic strategies primarily rely on the rational design of medical protocols (e.g., sequence and timing of agent administration; drug selectivity; compatibility of combined therapies i.e., adoptive T cell or agents, i.e., MEK inhibitor trametinib, PD-1 and PDL-1 blockers). Improved therapeutic protocols shall overcome therapeutic limitations such as the (i) tolerability and safety (i.e., minimal toxic side-effects); (ii) progression free survival (e.g., reduced relapse disease frequency); (iii) duration response (i.e., decreased drug resistance). Eventually, multidisciplinary approaches are still requested (e.g., genomics for personalized medicine, nanomedicine to overcome low free-drug bioavailability and targeting, systematic search of “melanoma stem cells” to enhance the prognosis and develop more valuable theranostics). In this paper, I will mainly present and discuss the latest and promising treatments for advanced cutaneous melanomas.http://dx.doi.org/10.1155/2013/735282 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Farid Menaa |
spellingShingle |
Farid Menaa Latest Approved Therapies for Metastatic Melanoma: What Comes Next? Journal of Skin Cancer |
author_facet |
Farid Menaa |
author_sort |
Farid Menaa |
title |
Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_short |
Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_full |
Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_fullStr |
Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_full_unstemmed |
Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_sort |
latest approved therapies for metastatic melanoma: what comes next? |
publisher |
Hindawi Limited |
series |
Journal of Skin Cancer |
issn |
2090-2905 2090-2913 |
publishDate |
2013-01-01 |
description |
Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RA mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, the newly-approved immunotherapeutic, ipilimumab, produces durable responses in patients presenting CTLA-4 T-cell surface protein. Nevertheless, the possible synergy in combining these two therapeutic strategies primarily rely on the rational design of medical protocols (e.g., sequence and timing of agent administration; drug selectivity; compatibility of combined therapies i.e., adoptive T cell or agents, i.e., MEK inhibitor trametinib, PD-1 and PDL-1 blockers). Improved therapeutic protocols shall overcome therapeutic limitations such as the (i) tolerability and safety (i.e., minimal toxic side-effects); (ii) progression free survival (e.g., reduced relapse disease frequency); (iii) duration response (i.e., decreased drug resistance). Eventually, multidisciplinary approaches are still requested (e.g., genomics for personalized medicine, nanomedicine to overcome low free-drug bioavailability and targeting, systematic search of “melanoma stem cells” to enhance the prognosis and develop more valuable theranostics). In this paper, I will mainly present and discuss the latest and promising treatments for advanced cutaneous melanomas. |
url |
http://dx.doi.org/10.1155/2013/735282 |
work_keys_str_mv |
AT faridmenaa latestapprovedtherapiesformetastaticmelanomawhatcomesnext |
_version_ |
1725005174699720704 |